中文

Hong Kong Stocks · Free Data Page

BIOCYTOGEN-B 02315

BIOCYTOGEN-B: FY2025 revenue CN¥1.38B (+40.60% YoY); net income CN¥173.2M; 1 alert, 1 watch item out of 17 risk checks; no TTM dividend.
Close PriceHK$42.10Day +16.94%Market CapHK$18.81BP/E43.7xTTMP/B6.47xROE (FY2025)11.5%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for BIOCYTOGEN-B?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2019–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥169.9M in FY2019 to CN¥1.38B in FY2025 (6-year CAGR +41.8%).
  • Net income was negative in FY2019, FY2020, FY2021, FY2022, FY2023.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)0.350.530.720.981.38
YoY39.8%50.6%34.3%36.8%40.6%
Net Income (CNY B)-0.55-0.60-0.380.030.17
YoY————416.4%
Operating Cash Flow (CNY B)-0.37-0.30-0.080.210.37
ROE-43.7%-50.3%-39.6%4.1%11.5%
Gross Margin69.8%73.4%70.6%77.7%75.8%
Net Margin-153.9%-112.7%-53.4%3.4%12.6%
Debt-to-Assets45.6%58.9%67.7%65.3%41.5%
Show all 7 fiscal years
Fiscal Year2019202020212022202320242025
Revenue (CNY B)0.170.250.350.530.720.981.38
YoY—49.3%39.8%50.6%34.3%36.8%40.6%
Net Income (CNY B)-0.26-0.43-0.55-0.60-0.380.030.17
YoY——————416.4%
Operating Cash Flow (CNY B)-0.04-0.23-0.37-0.30-0.080.210.37
ROE——-43.7%-50.3%-39.6%4.1%11.5%
Gross Margin57.2%65.9%69.8%73.4%70.6%77.7%75.8%
Net Margin-155.0%-168.8%-153.9%-112.7%-53.4%3.4%12.6%
Debt-to-Assets141.3%—45.6%58.9%67.7%65.3%41.5%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

1Alert 1Watch 14Pass 1N/A

Items Flagged for Review

  • Alert

    Inventory DaysFinancial Quality

    186.1 days, prior FY 6.5 days(+2769%)

    FY2025 (ended 2025-12-31) · What is this?

  • Watch

    Profit WarningMaterial Events

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

No dividends paid over the trailing 12 months.

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.